The subscription period of NorDiag`s share issue was closed yesterday, Tuesday 10 April 2007. The share issue was oversubscribed with 26%.

The share issue was a rights issue in Norway of up to 1,176 470 Offer Shares issued by the Company to raise up to NOK 10 million in new equity. The Company`s shareholders had preferential rights.

The share issue followed listing of 9,799 982 shares issued as consideration in connection with the acquisition of Genpoint AS, and a private placement of 3,839,938 shares towards institutional investors.

`The completions of these transactions have created a company with a broader technology portfolio and stronger capital resources. Our ambition is to build a leading diagnostic company in selected niches in 3-5 years`, says CEO Mårten Wigstøl in a comment.

Contactperson: CEO Mårten Wigstøl, mob. 911 657 75

About NorDiag ASA
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline NorDiag is listed on Oslo Stock Exchange with ticker NORD.